細胞凋亡，血管新生，Protein Kinase抗化劑:藥物開發策略分析 是由出版商BioSeeker Group AB在2012年05月所出版的。
這份英文市場調查報告書包含6261 Pages 價格從美金5175起跳。
本報告以癌症治療藥開發上的細胞凋亡，血管新生及Protein Kinase抗化劑的機制、目標、影響領域為焦點，彙整各種的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 血管新生
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:影響血管新生的癌治療藥目標策略
- 使用中的化合物策略:影響血管新生各化合物策略的治療樂物競爭基準
- 影響藥品作用的血管新生的癌症症狀
- 開發平台和最佳投資組合計劃:影響癌症治療藥開發平台血管新生的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
第3章 Protein Kinase抗化劑
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:Protein Kinase抗化劑開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:各類型化合物的競爭基準
- Protein Kinase抗化劑的癌適應症症狀選擇
- 最佳投資組合計劃:Protein Kinase抗化劑開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
This triple analysis focuses on cancer drug development strategies by
mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase
Inhibitors. Each of these three individual parts is evaluated according to
standardized criteria in a five pillar pipeline drug assessment methodology to
compare drug development strategies in oncology. This makes it easy to find
and compare analysis not only within one single cancer focus area but also
between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date
development strategies for 234 drugs in oncology within the portfolio of 158
companies world-wide, from Ceased to Marketed. The report extensively analyses
their 181 identified drug targets, organized into 157 drug target strategies,
and assesses them in 69 cancer indications.
Part II: Angiogenesis
The angiogenesis report part comprises defined and up to date development
strategies for 239 drugs affecting angiogenesis in oncology within the
portfolio of 148 investigators, from Preclinical to Marketed. This report part
extensively analyses 174 identified targets of angiogenesis affecting drugs,
organized into 167 drug target strategies, and assesses them in 64 different
cancer indications.
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development
strategies for 409 protein kinase drugs (990 projects) within the portfolio of
160 investigators, from Ceased to Marketed. This report part extensively
analyses 133 identified targets of protein kinase drugs, organized into 200
drug target strategies, and assesses them in 57 different cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Apoptosis
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for
the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug
Target Strategies and 234 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic
Cancer Drugs by Compound Strategy(7 Compound Strategies)
- 9. Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer
Indications)
- 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234
Drugs)
- Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 7 Figures
- Tables: Includes 315 Tables
- Total Number of Pages: 1,617
Part II: Angiogenesis
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (174 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167
Drug Target Strategies and 239 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs
Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
- 9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in
Oncology (64 Cancer Indications)
- 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148
Investigators)
- 10. Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 7 Figures
- Tables: Includes 300 Tables
- Total Number of Pages: 1227
Part III: Protein Kinase Inhibitors
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (133 Drug Targets)
- 7. The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Protein Kinase
Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Protein Kinase
Drugs in Oncology by Compound Type (7 Compound Strategies)
- 9. Selecting Cancer Indications for Protein Kinase Therapeutics (57
Different Cancer Indications)
- 10. Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer
Therapeutic Pipeline by Investigator (160 Investigators)
- 12. Drug Index
- 13. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 302 Tables
- Total Number of Pages: 1442
This Report Includes the Following Companies:
- 4SC
- Abbott
- Abiogen
- Abraxis BioScience
- Acceleron Pharma
- Access
- ACT Biotech
- Active Biotech
- Adherex
- Advanced Cancer Therapeutics
- Advanced Life Sciences
- Advantagene
- Advaxis
- Advenchen
- AEgera
- AEterna Zentaris
- Agennix
- Aida Pharmaceuticals
- Aileron Therapeutics
- Alethia Biotherapeutics
- Alfacell
- Alnylam
- AlphaVax
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amphora
- Anadys Pharmaceuticals
- Anaphore
- Anavex Life Sciences
- Angiogen
- Angiogenex
- Angstrom Pharmaceuticals
- Ansaris
- Antisoma
- Aphios
- Apogenix
- ApopLogic Pharmaceuticals
- Apthera
- Arana Therapeutics
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Austrianova
- Avila Therapeutics
- Basilea Pharmaceutica
- Bayer
- Benitec
- Berkeley Lab
- BioAlliance Pharma
- BioAxone
- Biocad
- Biocompatibles
- Biogen Idec
- BioInvent
- BioLineRx
- Biomas
- Bionovo
- Biotecnol
- BioVex
- Boehringer Ingelheim
- Bolder BioTechnology
- Bristol-Myers Squibb
- BTG
- Callisto Pharmaceuticals
- CanBas
- Cancer Research Technology
- CDG Therapeutics
- Celecure
- Celera
- Celgene
- Cell Therapeutics
- CellCeutix
- Cellmid
- Cephalon
- ChemoCentryx
- Chemokine Therapeutics
- China Sky One Medical
- Chlorogen
- Choongwae
- Chroma Therapeutics
- Circadian Technologies
- Cleveland BioLabs
- CombinatoRx
- CompleGen
- Compugen
- Coronado Biosciences
- Critical Outcome Technologies
- Cue Biotech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cynvec
- CytImmune Sciences
- Cytochroma
- CytRx
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Deciphera Pharmaceuticals
- Dendreon
- DeveloGen
- Dyax
- Eisai
- Elara Pharmaceuticals
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Endocyte
- Enkam Pharmaceuticals
- EntreMed
- EpiCept
- Erimos
- Exelixis
- ExonHit Therapeutics
- Facet Biotech
- Five Prime Therapeutics
- Galapagos
- GammaCan
- Genentech
- Generex
- Genmab
- Genta
- Gerolymatos
- Geron
- GlaxoSmithKline
- GlycoGenesys
- Glycotope
- GPC Biotech
- Green Cross
- Hanmi
- Harbor BioSciences
- Hoffmann-La Roche
- Human Genome Sciences
- Hy BioPharma
- Idera Pharmaceuticals
- ImClone Systems
- ImmunoFrontier
- ImmunoGen
- ImmuPharma
- Incyte Corporation
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Inovio
- Insmed
- Insys Therapeutics
- Intradigm
- Introgen Therapeutics
- Isis Pharmaceuticals
- ISU ABXIS
- Johnson & Johnson
- KAI Pharmaceuticals
- Kalypsys
- Karus Therapeutics
- Keryx Biopharmaceuticals
- Kiadis
- Kirin Pharma
- Kringle Pharma
- Kyowa Hakko Kirin
- Lee's Pharmaceutical
- Leo
- Ligand
- Locus Pharmaceuticals
- Lorus Therapeutics
- MAT Biopharma
- MaxoCore Pharmaceuticals
- MediGene
- Medisyn Technologies
- Merck & Co
- Merck KGaA
- Mersana Therapeutics
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- MolMed
- Morvus Technology
- NeoPharm
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- NewSouth Innovations
- NicOx
- Nidus Laboratories
- NIH
- Nippon Shinyaku
- Non-industrial source
- Novacea
- NovaLead
- Novartis
- Novelix
- Novogen
- Oasmia
- Oncalis
- Onconova
- OncoTherapy Science
- Oncothyreon
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- PanaGin
- Patrys
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacopeia
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- Philogen
- PhiloGene
- Pierre Fabre
- Piramal
- Plexxikon
- Progen
- ProMetic Life Sciences
- Protein Sciences
- PTC Therapeutics
- QLT
- Reata Pharmaceuticals
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Rigel
- Rosetta Genomics
- Sanofi
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- SBI Biotech
- SBIO
- Scancell
- Schering-Plough
- SciClone Pharmaceuticals
- Seattle Genetics
- Semafore Pharmaceuticals
- Senesco Technologies
- Sigma-Tau
- Silence Therapeutics
- Simcere Pharmaceuticals
- Spear Therapeutics
- SRI International
- SuperGen
- Supratek Pharma
- Switch Pharma
- SymBio Pharmaceuticals
- Symbiotec
- SynDevRx
- Takeda
- Targa Therapeutics
- TargeGen
- Tau Therapeutics
- Taxolog
- Tekmira Pharmaceuticals
- Telik
- TetraLogic Pharmaceuticals
- Teva
- Thallion Pharmaceuticals
- Theryte
- ThromboGenics
- Tigris Pharmaceuticals
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- UCB
- UMN Pharma
- ValiRx
- VasGene Therapeutics
- VBL Therapeutics
- Velacor Therapeutics
- Vertex Pharmaceuticals
- Vical
- Wilex
- VioQuest
- Viragen
- Viralytics
- ViroMed
- ViroTarg
- VM Discovery
- Wyeth
- Xencor
- Xerion
A Shortlist of Drugs Included are:
- 131I-tositumomab
- AEG-35156
- aflibercept
- alvocidib
- AME-133
- apatinib
- APG-101
- ARQ-197
- AS-101
- AS-1411
- axitinib
- bardoxolone methyl
- belinostat
- bevacizumab
- BIBF-1120
- BIBW-2992
- bortezomib
- bosutinib
- brivanib alaninate
- BZL-101
- canfosfamide hydrochloride
- cediranib
- cenersen
- cilengitide
- cintredekin besudotox
- conatumumab
- crolibulin
- dasatinib
- deforolimus
- dinaciclib
- dulanermin
- E-75
- endostatin
- enzastaurin hydrochloride
- erlotinib
- everolimus
- fosbretabulin tromethamine
- gataparsen
- gefitinib
- GT-111
- HBP-347
- HE-3235
- ibritumomab tiuxetan
- idronoxil
- imatinib mesilate
- imetelstat
- INGN-241
- kahalalide F
- lapatinib ditosylate
- lestaurtinib
- linifanib
- litronesib
- lonaprisan
- lumiliximab
- mapatumumab
- midostaurin
- MKC-1
- mocetinostat
- motesanib diphosphate
- motexafin gadolinium
- navitoclax
- nilotinib
- noscapine
- obinutuzumab
- oblimersen sodium
- ON-01910
- Oncohist
- OTS-102
- panobinostat
- PAT-SC1
- patupilone
- pazopanib hydrochloride
- PBI-1402
- PCI-24781
- plitidepsin
- PX-12
- quarfloxacin
- quinacrine
- R-(-)-gossypol
- RAF-265
- ramucirumab
- retaspimycin
- ridaforolimus
- sagopilone
- seliciclib
- sorafenib tosylate
- SPC-2996
- s-lapachone
- SU-6668
- sunitinib malate
- talactoferrin alfa
- tanespimycin
- temsirolimus
- terameprocol
- thymalfasin
- tigapotide triflutate
- tigatuzumab
- tipifarnib
- TL-32711
- triciribine phosphate
- TRU-016
- vandetanib
- volasertib
- vosaroxin
- XL-147
- XL-184
- XL-647
